AstraZeneca PLC Director/PDMR Shareholding (4334S)
November 15 2021 - 10:00AM
UK Regulatory
TIDMAZN
RNS Number : 4334S
AstraZeneca PLC
15 November 2021
15 November 2021 16:00 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 12 November 2021
an award of AstraZeneca American Depositary Shares (ADSs) vested to
Dr Aradhana Sarin, Chief Financial Officer. Each ADS represents one
half of an Ordinary Share of $0.25 in the Company.
In accordance with the Agreement and Plan of Merger, the award
was granted under the AstraZeneca Global Restricted Stock Plan at
the time of closing of the acquisition of Alexion Pharmaceuticals,
Inc. (Alexion) by the Company. It replaced Restricted Stock Units
held by Dr Sarin under the Alexion 2017 Incentive Plan, granted in
November 2017. The replacement award vested on the completion of
the original four-year holding period.
Following the withholding of shares to satisfy certain tax
obligations arising on vesting, 5,108 ADSs vested.
For tax purposes, the fair market value of an ADS at vest of the
award was US$62.92, being the closing price on the last trading day
preceding the vesting.
Further details are set out in the attached notification, made
in accordance with the requirements of the EU Market Abuse
Regulation (as it forms part of UK law pursuant to the European
Union (Withdrawal) Act 2018.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Aradhana Sarin
-------------------------- -----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- -----------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- -----------------------------------------
4i Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the AstraZeneca PLC American Depositary
financial instrument, Shares
type of instrument
Identification code CUSIP: 046353108
-------------------------- -----------------------------------------
b) Nature of the transaction Acquisition of AstraZeneca PLC American
Depository Shares pursuant to a vesting
under the Global Restricted Stock
Plan
-------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 5,108
----------
-------------------------- -----------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- -----------------------------------------
e) Date of the transaction 12 November 2021
-------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -----------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUVSVRARUAAAA
(END) Dow Jones Newswires
November 15, 2021 11:00 ET (16:00 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Mar 2023 to Mar 2024